Diffuse Large B Cell Lymphoma (DLBCL)

📋 Key Information Summary

📋

Diffuse Large B Cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, accounting for approximately 30–40% of all NHL diagnoses in Australia.
Front-line treatment is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) × 6 cycles, achieving durable remission in ~60% of patients.
Gene expression profiling classifies DLBCL into germinal-centre B-cell (GCB) and activated B-cell (ABC) subtypes — ABC has inferior outcomes with R-CHOP alone.
The International Prognostic Index (IPI) remains the standard risk-stratification tool; age >60, Ann Arbor stage III–IV, elevated LDH, ECOG ≥2, and ≥2 extranodal sites drive risk.
PET-CT is mandatory for staging (Lugano 2014 criteria) and interim/end-of-treatment response assessment using Deauville 5-point scale.
Excisional or large-core biopsy is essential — fine-needle aspiration is inadequate for histological subtyping and molecular testing.
Primary refractory or relapsed DLBCL is managed with platinum-based salvage chemotherapy (R-DHAP, R-ICE, or R-GDP) followed by autologous stem cell transplant (ASCT) in chemosensitive patients.
Chimeric antigen receptor T-cell (CAR-T) therapy (tisagenlecleucel or axicabtagene ciloleucel) is available at designated Australian centres for relapsed/refractory disease post-2 salvage lines.
Central nervous system prophylaxis with intrathecal methotrexate is indicated for high-risk sites (testicular, breast, paraspinal) and patients with CNS-IPI ≥4.
Aboriginal and Torres Strait Islander peoples have higher rates of advanced-stage presentation and reduced access to specialist haematology services in remote areas.
Cardiotoxicity screening (echocardiography, troponin) is essential prior to anthracycline-containing regimens, particularly in patients aged >65 or with cardiovascular risk factors.
Positron emission tomography — computed tomography (PET-CT) is funded under Medicare for staging and response assessment of aggressive lymphomas.

Introduction & Australian Epidemiology

Diffuse Large B Cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL) worldwide and in Australia, representing approximately 30–40% of all new NHL diagnoses. In Australia, there are an estimated 1,400–1,800 new cases of DLBCL per year, with an age-standardised incidence rate of approximately 5.5 per 100,000 population. The median age at diagnosis is 65–70 years, although the disease can present at any age.

DLBCL is characterised by rapid growth and aggressive clinical behaviour, but it is potentially curable with appropriate chemotherapy. The introduction of the anti-CD20 monoclonal antibody rituximab to standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone) — forming the R-CHOP regimen — has significantly improved outcomes. Approximately 60–65% of patients achieve durable remission with first-line R-CHOP, representing a true cure in the majority.

Despite this, 30–40% of patients will either fail to achieve remission (primary refractory disease) or relapse after initial response. Outcomes for these patients remain poor, with fewer than 20% achieving long-term survival with conventional salvage therapy and autologous stem cell transplant (ASCT). Novel therapies, including CAR-T cell therapy, bispecific antibodies, and targeted agents, are transforming the treatment landscape for relapsed/refractory disease.

Understanding the molecular heterogeneity of DLBCL — particularly the distinction between germinal-centre B-cell (GCB) and activated B-cell (ABC) subtypes — is increasingly important for risk stratification and emerging precision medicine approaches.

Pathogenesis & Molecular Subtypes

Cell of Origin Classification

Gene expression profiling (GEP) using microarray technology classifies DLBCL into two principal molecular subtypes based on the putative cell of origin:

Feature	GCB Subtype	ABC Subtype
Proportion of DLBCL	~45–50%	~35–40%
Cell of origin	Germinal-centre B lymphocyte	Post-germinal-centre plasmablast
Key genetic features	BCL2 translocation t(14;18), BCL6 translocation, EZH2 mutation, PTEN deletion	MYD88 L265P, CD79B mutation, CARD11 mutation, trisomy 3, NF-κB pathway activation
R-CHOP 5-year OS	~70–75%	~45–55%
Emerging targets	EZH2 inhibitors (tazemetostat), BTK inhibitors in select cases	BTK inhibitors (ibrutinib), lenalidomide, NF-κB pathway inhibitors
Immunohistochemical surrogate	Hans algorithm: CD10+ or CD10−/BCL6+/MUM1−	Hans algorithm: CD10−/BCL6− or CD10−/BCL6+/MUM1+

Immunohistochemical Surrogate (Hans Algorithm)

In routine Australian pathology practice, gene expression profiling is not universally available. The Hans immunohistochemical (IHC) algorithm serves as a validated surrogate, using CD10, BCL6, and MUM1/IRF4 staining to classify cases as GCB or non-GCB (used as a proxy for ABC). Concordance between IHC and GEP is approximately 80%.

Double-Hit and Triple-Hit Lymphomas

🚨

High-risk entity: "Double-hit" lymphomas harbour concurrent MYC and BCL2 and/or BCL6 translocations. These tumours — classified as high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in the WHO 5th edition — have extremely poor outcomes with R-CHOP (median OS <12 months). Intensified regimens (DA-EPOCH-R) are recommended. Fluorescence in situ hybridisation (FISH) for MYC, BCL2, and BCL6 should be performed in all cases with high-grade morphology or MYC protein expression ≥40% by IHC.

Double-Expresser Lymphomas

Cases demonstrating concurrent overexpression of MYC (≥40%) and BCL2 (≥50%) by immunohistochemistry without underlying translocations are termed "double-expresser" lymphomas. These represent approximately 20–30% of DLBCL, are enriched in ABC subtype, and have inferior outcomes with R-CHOP. Clinical trials evaluating DA-EPOCH-R and targeted agents in this population are ongoing.

Clinical Features & Staging

Presentation

DLBCL typically presents with rapidly enlarging lymphadenopathy, often with B symptoms (fever >38°C, drenching night sweats, unintentional weight loss >10% over 6 months). Extranodal involvement occurs in approximately 30–40% of cases and may be the sole presenting site.

Clinical Feature	Frequency	Notes
Peripheral lymphadenopathy	~70%	Rapidly enlarging, often painless, cervical most common
B symptoms	~30–40%	Associated with advanced stage and higher IPI
Elevated LDH	~55%	Reflects tumour bulk and proliferation rate
Extranodal disease	~30–40%	GI tract, bone, testis, breast, CNS, skin
Bulky disease (≥7.5 cm)	~25%	May influence consolidation radiotherapy decisions
CNS involvement at diagnosis	~2–5%	Parenchymal or leptomeningeal; high mortality

Ann Arbor Staging (Lugano Modification 2014)

Stage I

Single Node Region

Involvement of a single lymph node region or single extranodal site (IE).

~10–15% of DLBCL

Stage II

Two or More Regions — Same Side

Two or more lymph node regions on the same side of the diaphragm.

~20–25% of DLBCL

Stage III

Both Sides of Diaphragm

Lymph node regions on both sides of the diaphragm.

~15–20% of DLBCL

Stage IV

Diffuse Extranodal Involvement

Diffuse involvement of one or more extranodal organs (e.g. bone marrow, liver, lungs) with or without lymph node involvement.

~30–40% of DLBCL

International Prognostic Index (IPI)

The IPI remains the standard prognostic tool for DLBCL in clinical practice. Each factor scores 1 point:

Age >60 years
Serum LDH above normal
ECOG performance status ≥2
Ann Arbor stage III or IV
≥2 extranodal sites of disease

IPI Score	Risk Group	5-Year OS (R-CHOP era)
0–1	Low	~90%
2	Low-intermediate	~80%
3	High-intermediate	~60%
4–5	High	~40–50%

Revised IPI (R-IPI) and NCCN-IPI

The Revised IPI (R-IPI) reclassifies patients into three groups (very good, good, poor) and may better discriminate outcomes in the rituximab era. The NCCN-IPI incorporates additional granularity in LDH ratio and extranodal site definitions, further refining high-risk identification.

Investigations

Histopathological Diagnosis

⚠️

Excisional biopsy required: Fine-needle aspiration (FNA) alone is inadequate for DLBCL diagnosis. An excisional lymph node biopsy or large-core biopsy (≥14G, multiple cores) is essential to allow architectural assessment, immunophenotyping, and molecular studies.

The diagnostic work-up of suspected DLBCL requires:

Essential

Excisional or large-core biopsy

Morphology, immunohistochemistry panel (CD20, CD10, BCL6, MUM1, BCL2, MYC, Ki-67), MYC/BCL2/BCL6 FISH in high-grade morphology or MYC IHC ≥40%

Essential

PET-CT (whole body)

MBS item 61430 (PET for staging lymphoma). Lugano staging criteria. Deauville scoring for response assessment.

Essential

Bone marrow biopsy

May be omitted if PET-CT is negative (Lugano 2014). Aspirate and trephine for morphology, flow cytometry, and cytogenetics.

Available

Serum LDH

IPI component, tumour bulk surrogate, monitoring marker. Medicare-rebated.

Available

Full blood count, renal function, liver function, U&E, hepatitis B/C serology, HIV

Hepatitis B screening mandatory before rituximab (risk of reactivation). HIV testing recommended in all patients.

Available

Echocardiography (or MUGA scan)

Baseline LVEF assessment before anthracycline (doxorubicin). MBS item 55117.

Available

Cardiac troponin (high-sensitivity)

Baseline and serial monitoring for anthracycline cardiotoxicity.

Specialist

FISH for MYC, BCL2, BCL6

Essential when MYC IHC ≥40% or high-grade morphology. Identifies double/triple-hit lymphomas. Available at major Australian pathology networks (Sonic, Douglass Hanly Moir, SA Pathology).

Specialist

Cell-of-origin classification (GCB vs ABC)

Hans IHC algorithm standard. NanoString Lymphoma Subtyping Test (LST) or targeted NGS available at select tertiary centres. Recommended by RANZCOH for risk stratification.

Referral

Lumbar puncture with CSF cytology/flow cytometry

Indicated if testicular, breast, paraspinal, renal, or adrenal involvement; CNS-IPI ≥4; or neurological symptoms. Intrathecal methotrexate prophylaxis if high-risk.

Referral

MRI brain (with gadolinium)

If neurological symptoms or high CNS-IPI. More sensitive than CT for parenchymal and leptomeningeal disease.

CNS-IPI Score

The CNS-IPI identifies patients at high risk of CNS relapse. One point each for: age >60, LDH elevated, ECOG >1, stage III/IV, extranodal site >1, kidney and/or adrenal involvement. Score 4–6 = high risk (12–15% 2-year CNS relapse); consider CNS prophylaxis.

Management

First-Line Treatment: R-CHOP-21

R-CHOP-21 (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone administered every 21 days) remains the standard first-line regimen for DLBCL in Australia. The regimen is given for 6 cycles in stage I–II non-bulky disease and 6–8 cycles in advanced-stage disease, with consolidation radiotherapy considered for residual bulky sites.

💊

Rituximab

MabThera® · Riximyo® · Anti-CD20 monoclonal antibody

Adult dose 375 mg/m² IV Day 1 of each cycle

Paediatric dose 375 mg/m² IV (dose as per BFM protocol for paediatric mature B-NHL)

Renal adjustment Not required

Hepatic adjustment Not established — use with caution

PBS status ✔ PBS General Benefit (for NHL)

💊

Cyclophosphamide

Endoxan® · Cytoxan® · Alkylating agent

Adult dose 750 mg/m² IV Day 1 of each cycle

Renal adjustment Reduce by 25–50% if CrCl <10 mL/min

PBS status ✔ PBS General Benefit

💊

Doxorubicin

Adriamycin® · Anthracycline

Adult dose 50 mg/m² IV Day 1 of each cycle (lifetime cumulative max 450 mg/m²)

Key caution Cardiotoxicity — LVEF monitoring required. Avoid if LVEF <50%.

PBS status ✔ PBS General Benefit

💊

Vincristine

Oncovin® · Vinca alkaloid

Adult dose 1.4 mg/m² IV Day 1 (cap at 2 mg per dose)

Key caution Peripheral neuropathy — cumulative dose-related. Dose cap at 2 mg to reduce neurotoxicity.

PBS status ✔ PBS General Benefit

💊

Prednisolone

Solone® · Panafcortelone® · Corticosteroid

Adult dose 100 mg PO daily, Days 1–5 of each 21-day cycle

PBS status ✔ PBS General Benefit

⚠️

Hepatitis B screening mandatory: All patients must be screened for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), and hepatitis B surface antibody (anti-HBs) before commencing rituximab. Patients who are HBsAg-positive or anti-HBc-positive require antiviral prophylaxis (entecavir or tenofovir) for the duration of treatment and for ≥12 months post-completion, with hepatology co-management.

Treatment by Stage

Limited stage (I–II), non-bulky, no adverse features

R-CHOP × 3 cycles + involved-field radiotherapy (IFRT 30–36 Gy)

3 cycles + RT

Combined modality per RICOVER-60 and SWOG 0014 data

Limited stage (I–II), bulky (≥7.5 cm) or with adverse features

R-CHOP × 6 cycles ± IFRT to residual bulky disease

6 cycles ± RT

Treat as advanced stage if adverse risk factors present

Advanced stage (III–IV)

R-CHOP × 6 cycles (8 if slow response)

6 cycles (8 if indicated)

PET-guided consolidation RT to initial bulky or residual FDG-avid sites

CNS Prophylaxis

Intrathecal methotrexate (12–15 mg per injection, weekly × 4–6 doses) is indicated for patients with high CNS-IPI (4–6), testicular DLBCL, breast DLBCL, or other high-risk extranodal sites. Some centres utilise systemic high-dose methotrexate (3 g/m² × 2–4 doses) as an alternative to intrathecal therapy, particularly for parenchymal CNS risk.

💊

Intrathecal Methotrexate

Antimetabolite — CNS prophylaxis

Adult dose 12–15 mg intrathecal, weekly × 4–6 doses

Key caution Preservative-free formulation mandatory. Monitor for chemical arachnoiditis.

PBS status ✔ PBS General Benefit

Salvage Therapy for Relapsed/Refractory DLBCL

Patients with primary refractory disease or relapse after R-CHOP should be evaluated for salvage chemotherapy and autologous stem cell transplant (ASCT) if chemosensitive and fit for transplant. Eligibility should be assessed at a transplant-capable centre.

💊

R-DHAP

Rituximab + Dexamethasone + High-dose Cytarabine + Cisplatin

Regimen Rituximab 375 mg/m² IV D1; Dexamethasone 40 mg PO/IV D1–4; Cytarabine 2 g/m² IV BD D2; Cisplatin 100 mg/m² IV continuous infusion D1

Cycles Every 21 days × 2–3 cycles

Renal adjustment Cisplatin contraindicated if CrCl <60 mL/min — use R-GDP or R-ICE instead

PBS status ✔ PBS General Benefit

💊

R-ICE

Rituximab + Ifosfamide + Carboplatin + Etoposide

Regimen Rituximab 375 mg/m² IV D1; Ifosfamide 5 g/m² IV continuous infusion D2 (with mesna); Carboplatin AUC 5 IV D2; Etoposide 100 mg/m² IV D1–3

Cycles Every 14–21 days × 2–3 cycles

PBS status ✔ PBS General Benefit

💊

R-GDP

Rituximab + Gemcitabine + Dexamethasone + Cisplatin/Carboplatin

Regimen Rituximab 375 mg/m² IV D1; Gemcitabine 1000 mg/m² IV D1, D8; Dexamethasone 40 mg PO D1–4; Cisplatin 75 mg/m² IV D1 (or carboplatin AUC 5)

Cycles Every 21 days × 2–3 cycles

PBS status ✔ PBS General Benefit

Autologous Stem Cell Transplant (ASCT)

ASCT remains the standard consolidation for patients with chemosensitive relapsed DLBCL (partial or complete metabolic response to salvage therapy), as established by the PARMA trial. BEAM (carmustine, etoposide, cytarabine, melphalan) is the most widely used conditioning regimen in Australia. ASCT is performed at designated transplant centres across major Australian cities (Royal Adelaide Hospital, Peter MacCallum Cancer Centre, Westmead Hospital, Royal Brisbane and Women's Hospital, etc.).

CAR-T Cell Therapy

✅

Funded in Australia: Chimeric antigen receptor T-cell (CAR-T) therapy is available under the Pharmaceutical Benefits Scheme (PBS) for relapsed/refractory DLBCL after ≥2 lines of systemic therapy. Tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) are PBS-listed (Authority Required) and administered at approved cell-therapy centres. Referral to a CAR-T accredited centre should occur early in the treatment course for transplant-eligible patients.

💊

Tisagenlecleucel

Kymriah® · Anti-CD19 CAR-T cell therapy

Adult dose 0.6–6.0 × 10⁸ CAR-positive viable T cells IV (single infusion) after lymphodepletion (fludarabine + cyclophosphamide)

Indication Relapsed/refractory DLBCL after ≥2 lines of therapy

Key caution Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) — tocilizumab and corticosteroid for management

PBS status Authority Required — Specialist centres only

💊

Axicabtagene ciloleucel

Yescarta® · Anti-CD19 CAR-T cell therapy

Adult dose 2.0 × 10⁶ CAR-positive viable T cells/kg IV (single infusion) after lymphodepletion (fludarabine + cyclophosphamide)

Indication Relapsed/refractory DLBCL after ≥2 lines of therapy

PBS status Authority Required — Specialist centres only

Novel and Emerging Agents

Several agents are in late-phase clinical trials or have received TGA registration for specific DLBCL subpopulations:

Polatuzumab vedotin (anti-CD79b antibody-drug conjugate) — TGA-approved in combination with bendamustine + rituximab for relapsed/refractory DLBCL. PBS-listed (Authority Required).
Tafasitamab (anti-CD19 antibody) + lenalidomide — approved for relapsed/refractory DLBCL ineligible for ASCT. Available via special access schemes in Australia.
Bispecific antibodies (glofitamab, epcoritamab, mosunetuzumab) — anti-CD20 × CD3 T-cell engagers showing promising response rates in heavily pre-treated DLBCL. Glofitamab TGA-approved; PBS listing under review.
Selitrectinib (LOXO-305) and pirtobrutinib — non-covalent BTK inhibitors under investigation for ABC-DLBCL.

Monitoring

During Treatment

Each cycle (Day 1)

Full blood count (FBC), renal function, liver function tests, LDH. Assess for infusion-related reactions with rituximab. Review ECOG performance status.

Cycle 3–4 (interim PET-CT)

Interim PET-CT with Deauville scoring. Deauville 1–3 = adequate metabolic response, continue R-CHOP. Deauville 4–5 may prompt clinical trial enrolment or treatment intensification discussion at multidisciplinary team (MDT) meeting.

Cycles 2, 4, 6

Echocardiography or troponin monitoring if cumulative doxorubicin approaching 300 mg/m² or clinical concern for cardiotoxicity.

End of Treatment

6–8 weeks post-completion

End-of-treatment PET-CT (Deauville scoring). Complete metabolic response (CMR) = Deauville 1–3. Post-treatment LDH, FBC, renal function.

Post-Treatment Surveillance

Routine surveillance after confirmed complete response (CR) follows institutional protocols, generally:

Clinical review every 3 months for years 1–2, every 6 months for years 3–5, then annually
FBC, LDH, renal and liver function at each visit
CT only if clinically indicated — routine CT surveillance is not recommended by Lugano 2014 or NCCN guidelines as most relapses present symptomatically or with LDH elevation
Thyroid function testing if prior neck radiotherapy
Psychosocial support, fertility counselling (pre-treatment), and survivorship care plan

ℹ️

Response assessment (Lugano 2014): Complete metabolic response (CMR) = Deauville 1–3 with residual mass ≤ normal nodal size. Partial metabolic response = Deauville 4–5 with reduced uptake from baseline. Progressive metabolic disease = Deauville 4–5 with increased uptake or new FDG-avid lesions.

Special Populations

🤰 Pregnancy

First trimester

R-CHOP is teratogenic (anthracycline, cyclophosphamide). Deferral of treatment to second trimester if clinically feasible. If urgent treatment required, consider dose-adjusted R-CHOP with obstetric co-management. Rituximab crosses the placenta in the second/third trimester — monitor neonatal B-cell counts post-delivery.

Second/third trimester

R-CHOP can be administered with careful monitoring. Avoid vincristine in the third trimester if delivery is anticipated within 14 days (risk of vocal cord paralysis in neonate). Plan delivery between cycles when blood counts are recovering. Multidisciplinary obstetric–haematology team essential.

👶 Paediatrics

Treatment approach

Paediatric DLBCL is managed according to mature B-cell non-Hodgkin lymphoma protocols (BFM/NHL-BFM or LMB). R-CHOP is not the standard paediatric regimen. Intensive short-pulse chemotherapy with rituximab (e.g. R-COPADM, R-CYVE) achieves >90% event-free survival in paediatric DLBCL/Burkitt. Referral to a paediatric oncology centre (e.g. Children's Hospital at Westmead, RCH Melbourne) is mandatory.

👴 Elderly (≥70 years)

Dose modification

Full-dose R-CHOP remains appropriate for fit elderly patients (comprehensive geriatric assessment recommended). Dose-reduced R-miniCHOP (attenuated CHOP) is a validated alternative for frail patients aged >80 or those with significant comorbidities. Rituximab is maintained at full dose. Cardiotoxicity risk is higher — baseline and serial echocardiography essential.

R-miniCHOP regimen

Rituximab 375 mg/m² IV D1; Doxorubicin 25 mg/m² IV D1; Cyclophosphamide 400 mg/m² IV D1; Vincristine 1 mg IV D1 (fixed dose); Prednisolone 40 mg/m² PO D1–5. Every 21 days × 6 cycles.

🫘 Renal Impairment

R-CHOP

Cyclophosphamide requires dose reduction if CrCl <10 mL/min (reduce by 25–50%). Vincristine and doxorubicin do not require renal dose adjustment. Rituximab does not require renal adjustment. For salvage, avoid cisplatin-based regimens (R-DHAP) if CrCl <60 mL/min — use R-ICE or R-GDP (carboplatin-based) instead.

🫁 Hepatic Impairment

Dose considerations

Cyclophosphamide and doxorubicin are hepatically metabolised. Use caution in significant hepatic impairment (bilirubin >3× ULN). Consider dose reduction of doxorubicin by 50% if bilirubin 1.5–3× ULN, and 75% if >3× ULN. Consult with specialist pharmacist and hepatologist.

🛡️ Immunocompromised (HIV-associated DLBCL)

HIV-positive patients

R-CHOP is standard first-line for HIV-associated DLBCL, administered concurrently with combination antiretroviral therapy (cART). Dose reduction is not required if CD4 count >200 cells/µL and HIV viral load is suppressed. Monitor for opportunistic infections, neutropenia, and drug interactions (azoles, NNRTIs, protease inhibitors). Co-manage with infectious diseases/HIV specialist. CNS prophylaxis with intrathecal methotrexate is recommended given higher CNS relapse risk.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology & disparities

Aboriginal and Torres Strait Islander Australians experience a higher incidence of aggressive lymphomas, including DLBCL, and present at a more advanced stage compared with non-Indigenous Australians. AIHW data demonstrate lower 5-year survival rates for Indigenous Australians with NHL, driven by later diagnosis, comorbidities (diabetes, renal disease, cardiovascular disease), and reduced access to timely specialist care.

Geographic & systemic barriers

Many Indigenous Australians live in regional, rural, or remote communities with limited access to haematology specialists, PET-CT scanners, and transplant centres. Treatment may require relocation to metropolitan centres (often hundreds or thousands of kilometres away), creating significant disruption to family, community, and cultural connections. Patient-assisted travel schemes (PATS) are available but may be underutilised due to administrative complexity.

Culturally safe care

Health literacy considerations require culturally appropriate education materials (pictorial, translated into local languages where relevant). Aboriginal Health Workers and Aboriginal Liaison Officers should be integral members of the care team. Yarning-based consultation styles, family-centred decision-making, and acknowledgement of sorry business/cultural obligations should be incorporated into treatment planning. Men's and women's business considerations may influence examination and treatment delivery.

Comorbidity burden

Higher prevalence of renal impairment, cardiovascular disease, diabetes, and hepatitis B among Indigenous Australians may impact chemotherapy tolerability, cardiotoxicity risk, and infection risk. Baseline renal function, cardiac assessment, and hepatitis B screening are especially important. Dose modifications may be required more frequently.

Timely referral

GPs and Aboriginal Community Controlled Health Organisations (ACCHOs) should maintain a low threshold for investigation of persistent lymphadenopathy, B symptoms, or unexplained weight loss. Early referral to regional cancer centres (e.g. Royal Darwin Hospital, Cairns Hospital, Alice Springs Hospital) for biopsy and staging reduces diagnostic delay. Telehealth haematology consultations facilitate specialist input without requiring patient travel.

Support services

Referral to Indigenous-specific cancer support services including Cancer Council Australia's Aboriginal and Torres Strait Islander programs, McGrath Foundation Breast Care Nurses (for breast DLBCL), local ACCHO health services, and social and emotional wellbeing teams. Financial assistance through Closing the Gap PBS co-payment measures reduces medication costs for eligible Indigenous patients.

📚 References

1. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–5033.
2. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
6. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994.
7. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
8. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540–1545.
9. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
10. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
11. Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
12. Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. Canberra: AIHW; 2024. Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia
13. Australasian Leukaemia & Lymphoma Group (ALLG). ALLG clinical trial network. Available from: https://www.allg.org.au
14. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022.
15. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v116–v125.